Gleamer, the French company specializing in AI-powered solutions for radiology, recently announced it has acquired Pixyl and Caerus Medical, two companies working on AI-powered products to assist in identifying anomalies in neural and lumbar MRI scans, respectively. Pixyl's flagship product is Pixyl.Neuro, an FDA and CE-approved solution that uses AI to identify abnormalities related to neuroinflammatory and neurodegenerative disorders in brain MRI scans. As for Caerus Medical, the company debuted in the AI-assisted radiology market with LumbarMR, which helps radiologists and other healthcare professionals identify and diagnose lumbar disorders on MRI scans.

With these strategic transactions, Gleamer will grow its portfolio of AI-powered radiology solutions, which was previously focused on specific types of CT and X-ray imaging, including mammograms. The company announced that BreastView, its solution to support breast cancer detection, achieved CE-certification just last month. Previously, Gleamer shared a five-year plan to develop an oncology-specific solution called OncoView, supported by €4.5 million from the French government's France 2030 program. These products, together with BoneView (bone trauma detection), ChestView (thoracic pathology detection), BoneMetrics (MSK measurement automation), and BoneAge (bone maturity assessment), comprised the totality of Gleamer's portfolio before the acquisitions.

Gleamer aims to develop a 'general' AI copilot capable of assisting radiologists and other healthcare professionals on varied diagnostics tasks. However, in a recent interview with TechCrunch, Gleamer co-founder and CEO Christian Allouche admitted it may not be feasible to develop a single product that can do it all. "Unfortunately, the one-size-fits-all approach to radiology doesn’t work. It’s very complicated to have a large model that covers all medical imaging and delivers the level of performance expected by doctors," Allouche mentioned in the interview. Regardless, Gleamer seems to be doing quite well by creating (or acquiring) teams to focus on one diagnostics challenge at a time.